Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Platelet Aggregation Inhibitors"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 169
Tytuł:
Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
Autorzy:
Matchar DB; Center for Clinical Health Policy Research, Duke University, Durham, NC 27705, USA. />Samsa GP
Liu S
Pokaż więcej
Źródło:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2005 Sep-Oct; Vol. 8 (5), pp. 572-80.
Typ publikacji:
Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Models, Econometric*
Quality-Adjusted Life Years*
Aspirin/*economics
Brain Ischemia/*drug therapy
Dipyridamole/*economics
Intracranial Hemorrhages/*drug therapy
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*economics
Stroke/*prevention & control
Ticlopidine/*analogs & derivatives
Aged ; Aspirin/therapeutic use ; Brain Ischemia/economics ; Brain Ischemia/physiopathology ; Clopidogrel ; Computer Simulation ; Cost-Benefit Analysis ; Dipyridamole/therapeutic use ; Female ; Health Care Costs ; Humans ; Intracranial Hemorrhages/economics ; Intracranial Hemorrhages/physiopathology ; Male ; Myocardial Infarction/economics ; Myocardial Infarction/physiopathology ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/classification ; Proportional Hazards Models ; Randomized Controlled Trials as Topic ; Recurrence ; Risk ; Stroke/economics ; Stroke/mortality ; Ticlopidine/economics ; Ticlopidine/therapeutic use ; Uncertainty
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Autorzy:
Chen J; Yale University School of Medicine, New Haven, CT, USA.
Bhatt DL
Dunn ES
Shi C
Caro JJ
Mahoney EM
Gabriel S
Jackson JD
Topol EJ
Cohen DJ
Pokaż więcej
Źródło:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2009 Sep; Vol. 12 (6), pp. 872-9. Date of Electronic Publication: 2009 Mar 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Aspirin/*economics
Cardiovascular Diseases/*economics
Cardiovascular Diseases/*prevention & control
Platelet Aggregation Inhibitors/*economics
Ticlopidine/*analogs & derivatives
Aged ; Aspirin/therapeutic use ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/mortality ; Clopidogrel ; Cost-Benefit Analysis ; Databases, Factual ; Drug Therapy, Combination ; Female ; Health Care Costs ; Hospitalization/statistics & numerical data ; Humans ; Life Expectancy ; Male ; Middle Aged ; Multicenter Studies as Topic ; Platelet Aggregation Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Saskatchewan/epidemiology ; Secondary Prevention/economics ; Secondary Prevention/methods ; Survival Analysis ; Ticlopidine/economics ; Ticlopidine/therapeutic use ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
Autorzy:
Latour-Pérez J; Intensive Care Unit, Hospital General Universitario de Elche, Elche, Spain. />de Miguel Balsa E
Betegón L
Badia X
Pokaż więcej
Źródło:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2008 Sep-Oct; Vol. 11 (5), pp. 853-61. Date of Electronic Publication: 2008 May 16.
Typ publikacji:
Journal Article
MeSH Terms:
Acute Coronary Syndrome/*drug therapy
Aspirin/*economics
Platelet Aggregation Inhibitors/*economics
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Ticlopidine/*analogs & derivatives
Acute Coronary Syndrome/economics ; Aged ; Aspirin/therapeutic use ; Clopidogrel ; Confidence Intervals ; Cost-Benefit Analysis ; Drug Therapy, Combination ; Female ; Humans ; Male ; Markov Chains ; Models, Economic ; Platelet Aggregation Inhibitors/therapeutic use ; Quality-Adjusted Life Years ; Risk ; Risk Assessment ; Spain ; Ticlopidine/economics ; Ticlopidine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions.
Autorzy:
Long KH; Department of Health Sciences Research, Division of Health Care Policy and Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. />Ting HH
McMurtry EK
Lennon RJ
Wood DL
Holmes DR Jr
Raveendran G
Rihal CS
Pokaż więcej
Źródło:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2008 May-Jun; Vol. 11 (3), pp. 462-9.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angioplasty, Balloon, Coronary*/economics
Outcome Assessment, Health Care*
Antibodies, Monoclonal/*therapeutic use
Immunoglobulin Fab Fragments/*therapeutic use
Peptides/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Abciximab ; Antibodies, Monoclonal/economics ; Coronary Angiography ; Cost-Benefit Analysis ; Eptifibatide ; Humans ; Immunoglobulin Fab Fragments/economics ; Length of Stay/statistics & numerical data ; Logistic Models ; Longitudinal Studies ; Peptides/economics ; Platelet Aggregation Inhibitors/economics ; Proportional Hazards Models ; Prospective Studies ; Registries ; Statistics, Nonparametric
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The lady aspirin for cardiovascular disease.
Autorzy:
Verheugt FW; Department of Cardiology, Heartcentre, University Medical Centre, Nijmegen, Netherlands. />Smith SC Jr
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2005 Oct 01; Vol. 366 (9492), pp. 1148-50.
Typ publikacji:
Journal Article
MeSH Terms:
Aspirin/*administration & dosage
Cardiovascular Diseases/*prevention & control
Platelet Aggregation Inhibitors/*administration & dosage
Aged ; Aspirin/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction/prevention & control ; Platelet Aggregation Inhibitors/adverse effects ; Sex Factors ; Stroke/prevention & control
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study.
Autorzy:
Hanefeld C; Medical Clinic II (Cardiology & Angiology), St. Josef-Hospital/Berufsgenossenschaftliche Kliniken Bergmannsheil, University Hospitals of the Ruhr-University, Gudrunstrasse 56, D-44791 Bochum, Germany.
Sirtl C
Spiecker M
Bojara W
Grewe PH
Lawo T
Mügge A
Pokaż więcej
Źródło:
Chest [Chest] 2004 Sep; Vol. 126 (3), pp. 935-41.
Typ publikacji:
Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Emergency Medical Services*
Coronary Thrombosis/*drug therapy
Myocardial Infarction/*drug therapy
Peptides/*administration & dosage
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Aged ; Ambulances ; Berlin ; Coronary Thrombosis/blood ; Coronary Thrombosis/mortality ; Eptifibatide ; Feasibility Studies ; Female ; Hospital Mortality ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Myocardial Infarction/blood ; Myocardial Infarction/mortality ; Outcome Assessment, Health Care ; Peptides/adverse effects ; Pilot Projects ; Platelet Aggregation Inhibitors/adverse effects ; Survival Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
Autorzy:
Diener HC; Department of Neurology, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany. />Bogousslavsky J
Brass LM
Cimminiello C
Csiba L
Kaste M
Leys D
Matias-Guiu J
Rupprecht HJ
Pokaż więcej
Corporate Authors:
MATCH investigators
Źródło:
Lancet (London, England) [Lancet] 2004 Jul 24-30; Vol. 364 (9431), pp. 331-7.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Aspirin/*administration & dosage
Ischemic Attack, Transient/*prevention & control
Platelet Aggregation Inhibitors/*administration & dosage
Stroke/*prevention & control
Ticlopidine/*administration & dosage
Ticlopidine/*analogs & derivatives
Aged ; Aspirin/adverse effects ; Clopidogrel ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Hemorrhage/chemically induced ; Humans ; Intracranial Hemorrhages/chemically induced ; Male ; Platelet Aggregation Inhibitors/adverse effects ; Recurrence ; Risk Factors ; Ticlopidine/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Lessons from MATCH for future randomised trials in secondary prevention of stroke.
Autorzy:
Rothwell PM; Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford OX2 6HE, UK.
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2004 Jul 24-30; Vol. 364 (9431), pp. 305-7.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Aspirin/*administration & dosage
Platelet Aggregation Inhibitors/*administration & dosage
Stroke/*prevention & control
Ticlopidine/*administration & dosage
Ticlopidine/*analogs & derivatives
Aspirin/adverse effects ; Clopidogrel ; Drug Therapy, Combination ; Humans ; Ischemic Attack, Transient/prevention & control ; Platelet Aggregation Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Recurrence ; Risk Factors ; Ticlopidine/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain.
Autorzy:
Latour-Pérez J; Intensive Care Unit, Hospital General Universitario de Elche, Department of Public Health. Universidad de Alicante, Alicante, Spain. />Navarro-Ruiz A
Ridao-López M
Cervera-Montes M
Pokaż więcej
Źródło:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2004 Jan-Feb; Vol. 7 (1), pp. 52-60.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Costs*
Coronary Disease/*drug therapy
Coronary Disease/*economics
Platelet Aggregation Inhibitors/*economics
Ticlopidine/*analogs & derivatives
Ticlopidine/*economics
Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Clopidogrel ; Cost-Benefit Analysis ; Decision Trees ; Humans ; Markov Chains ; Middle Aged ; Monte Carlo Method ; Platelet Aggregation Inhibitors/therapeutic use ; Quality-Adjusted Life Years ; Spain ; Ticlopidine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Autorzy:
Topol EJ; Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA. />Mark DB
Lincoff AM
Cohen E
Burton J
Kleiman N
Talley D
Sapp S
Booth J
Cabot CF
Anderson KM
Califf RM
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 1999 Dec 11; Vol. 354 (9195), pp. 2019-24.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Angioplasty, Balloon, Coronary*/economics
Stents*/economics
Antibodies, Monoclonal/*administration & dosage
Coronary Disease/*therapy
Immunoglobulin Fab Fragments/*administration & dosage
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Adult ; Aged ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/economics ; Coronary Disease/blood ; Coronary Disease/economics ; Coronary Disease/mortality ; Cost-Benefit Analysis ; Death, Sudden, Cardiac/prevention & control ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Immunoglobulin Fab Fragments/economics ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/economics ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Platelet GPIIb-IIIa blockers.
Autorzy:
Topol EJ; Joseph J Jacobs Center for Thrombosis and Vascular Biology, Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA. />Byzova TV
Plow EF
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 1999 Jan 16; Vol. 353 (9148), pp. 227-31.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Platelet Aggregation Inhibitors*/chemistry
Platelet Aggregation Inhibitors*/therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block.
Autorzy:
Kodama-Takahashi K; Department of Internal Medicine, Yawatahama General Hospital, Japan. />Kurata A
Ohshima K
Yamamoto K
Uemura S
Watanabe S
Iwata T
Pokaż więcej
Źródło:
Chest [Chest] 2003 Apr; Vol. 123 (4), pp. 1161-9.
Typ publikacji:
Journal Article
MeSH Terms:
Heart Block/*physiopathology
Heart Conduction System/*drug effects
Platelet Aggregation Inhibitors/*pharmacology
Tetrazoles/*pharmacology
Aged ; Aged, 80 and over ; Atrial Natriuretic Factor/blood ; Cilostazol ; Electrocardiography ; Female ; Heart Block/blood ; Heart Block/therapy ; Humans ; Male ; Middle Aged ; Natriuretic Peptide, Brain/blood ; Pacemaker, Artificial ; Platelet Aggregation Inhibitors/therapeutic use ; Prospective Studies ; Tetrazoles/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Too much, too little, or none at all: dealing with substandard and fake drugs.
Autorzy:
Wan Po AL; Centre for Evidence-Based Pharmacotherapy, Aston University, Aston Triangle, B4 7ET, Birmingham, UK.
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2001 Jun 16; Vol. 357 (9272), pp. 1904.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Comment
MeSH Terms:
Myocardial Reperfusion*
Thrombolytic Therapy*
Antibodies, Monoclonal/*administration & dosage
Drug and Narcotic Control/*legislation & jurisprudence
Fibrinolytic Agents/*administration & dosage
Immunoglobulin Fab Fragments/*administration & dosage
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Recombinant Proteins/*administration & dosage
Tissue Plasminogen Activator/*administration & dosage
Abciximab ; Administration, Oral ; Aged ; Antibodies, Monoclonal/adverse effects ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents/adverse effects ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Infusions, Intravenous ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Recombinant Proteins/adverse effects ; Survival Rate ; Tissue Plasminogen Activator/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Autorzy:
Topol EJ; Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA.
Pokaż więcej
Corporate Authors:
GUSTO V Investigators
Źródło:
Lancet (London, England) [Lancet] 2001 Jun 16; Vol. 357 (9272), pp. 1905-14.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Myocardial Reperfusion*
Thrombolytic Therapy*
Antibodies, Monoclonal/*administration & dosage
Fibrinolytic Agents/*administration & dosage
Immunoglobulin Fab Fragments/*administration & dosage
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Recombinant Proteins/*administration & dosage
Tissue Plasminogen Activator/*administration & dosage
Abciximab ; Administration, Oral ; Aged ; Antibodies, Monoclonal/adverse effects ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents/adverse effects ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Infusions, Intravenous ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Recombinant Proteins/adverse effects ; Survival Rate ; Tissue Plasminogen Activator/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 169

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies